JP2002523363A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523363A5
JP2002523363A5 JP2000565867A JP2000565867A JP2002523363A5 JP 2002523363 A5 JP2002523363 A5 JP 2002523363A5 JP 2000565867 A JP2000565867 A JP 2000565867A JP 2000565867 A JP2000565867 A JP 2000565867A JP 2002523363 A5 JP2002523363 A5 JP 2002523363A5
Authority
JP
Japan
Prior art keywords
pain
treatment
fibromyalgia
patients
fatigue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000565867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523363A (ja
JP4510290B2 (ja
Filing date
Publication date
Priority claimed from GBGB9818467.4A external-priority patent/GB9818467D0/en
Priority claimed from GBGB9826692.7A external-priority patent/GB9826692D0/en
Application filed filed Critical
Priority claimed from PCT/EP1999/006215 external-priority patent/WO2000010545A2/en
Publication of JP2002523363A publication Critical patent/JP2002523363A/ja
Publication of JP2002523363A5 publication Critical patent/JP2002523363A5/ja
Application granted granted Critical
Publication of JP4510290B2 publication Critical patent/JP4510290B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000565867A 1998-08-25 1999-08-24 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 Expired - Fee Related JP4510290B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9818467.4 1998-08-25
GBGB9818467.4A GB9818467D0 (en) 1998-08-25 1998-08-25 Organic compounds
GBGB9826692.7A GB9826692D0 (en) 1998-12-04 1998-12-04 Organic compounds
GB9826692.7 1998-12-04
PCT/EP1999/006215 WO2000010545A2 (en) 1998-08-25 1999-08-24 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome

Publications (3)

Publication Number Publication Date
JP2002523363A JP2002523363A (ja) 2002-07-30
JP2002523363A5 true JP2002523363A5 (https=) 2010-05-13
JP4510290B2 JP4510290B2 (ja) 2010-07-21

Family

ID=26314255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000565867A Expired - Fee Related JP4510290B2 (ja) 1998-08-25 1999-08-24 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用

Country Status (14)

Country Link
US (5) US20030092735A1 (https=)
EP (1) EP1107744B1 (https=)
JP (1) JP4510290B2 (https=)
CN (1) CN1216598C (https=)
AT (1) ATE238044T1 (https=)
AU (1) AU5624599A (https=)
BR (1) BR9913201A (https=)
CA (1) CA2339628C (https=)
DE (1) DE69907220T2 (https=)
DK (1) DK1107744T3 (https=)
ES (1) ES2198948T3 (https=)
PT (1) PT1107744E (https=)
TW (1) TW200529847A (https=)
WO (1) WO2000010545A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265209T1 (de) 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
CN1306489C (zh) * 2002-09-30 2007-03-21 日本电气株式会社 记录条件设定方法及使用该方法的信息记录装置
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
CN101668527A (zh) * 2007-02-23 2010-03-10 阿韦拉制药股份有限公司 药物制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
DE69105131T2 (de) * 1990-06-01 1995-03-23 Pfizer 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
ES2229259T3 (es) * 1995-01-12 2005-04-16 Glaxo Group Limited Derivados de piperidina con actividad antagonista de taquiquinina.
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
WO1997038692A1 (en) 1996-04-12 1997-10-23 Eli Lilly And Company Bisindoles for treating pain or nociception
US5891875A (en) * 1996-05-20 1999-04-06 Eli Lilly And Company Morpholinyl tachykinin receptor antagonists
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
DE69732133T2 (de) 1996-12-02 2005-12-22 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia

Similar Documents

Publication Publication Date Title
Waters et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension-results of the TOPIC (Trial Of Physiotens In Combination) Study
US7713984B2 (en) Pharmaceutical uses
CN111032158A (zh) 用于治疗抑郁的nk-1拮抗剂组合物和方法
KR20170120708A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
JP2002523363A5 (https=)
EP2475371B1 (en) Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
Andersson Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril
WO2019023175A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
JP2008044879A (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品
HK40103286A (zh) 治疗与s1p₁受体相关的病症的方法
KR20220108123A (ko) 치매 환자의 행동 및 심리적 증상 치료
JP2004175786A (ja) Ｉ型アレルギー疾患治療用組成物
Howden Safety and tolerability of tegaserod for irritable bowel syndrome
JP2020172475A (ja) メロキシカム又はその薬学的に許容される塩を含有する内服治療剤
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.
JPH09136843A (ja) 血圧上昇薬
CA2495311A1 (en) Use of a quinazoline derivative for treating lower urinary tract symptoms